PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34183306-1	2021	Isocitrate dehydrogenase (IDH) mutations produce high levels of the "oncometabolite" R-2-hydroxyglutarate (R-2-HG) and play a key role in the initiation and progression of glioma tumors in the brain.	r-2-hydroxyglutarate	85-105	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	0-24	
34183306-1	2021	Isocitrate dehydrogenase (IDH) mutations produce high levels of the "oncometabolite" R-2-hydroxyglutarate (R-2-HG) and play a key role in the initiation and progression of glioma tumors in the brain.	r-2-hydroxyglutarate	85-105	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	26-29	
35609569-3	2022	In isocitrate dehydrogenase type 1 (IDH) mutant gliomas, monocyte-derived macrophages have recently been shown to display an attenuated intratumoral antigen presentation capacity as consequence of the local accumulation of the oncometabolite R-2-hydroxyglutarate.	r-2-hydroxyglutarate	242-262	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	36-39	
34188585-3	2021	A mutant IDH enzyme, existing in the cell cytoplasm and possessing neomorphic activity, converts alphaKG into oncometabolite R-2-hydroxyglutarate (R-2-HG) that accumulates in high amounts in the cell and inhibits alphaKG-dependent enzymes, including epigenetic regulators.	r-2-hydroxyglutarate	125-145	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	9-12	
32955829-3	2020	Mutant IDH enzymes have neomorphic activity and convert alphaKG to the oncometabolite R-2-hydroxyglutarate (R-2-HG) which accumulates at high levels in the cell and hampers the function of alphaKG-dependent enzymes, including epigenetic regulators, thus leading to altered gene expression and block of differentiation and contributing to leukemia development.	r-2-hydroxyglutarate	86-106	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	7-10	
35226770-2	2022	These hotspot gain-of-function mutations cause the IDH enzyme to aberrantly generate high levels of the oncometabolite, R-2-hydroxyglutarate, which competitively inhibits enzymes that regulate epigenetics, DNA repair, metabolism, and other processes.	r-2-hydroxyglutarate	120-140	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	51-54	
29249359-1	2018	R-2-hydroxyglutarate (R-2HG), produced at high levels by mutant isocitrate dehydrogenase 1/2 (IDH1/2) enzymes, was reported as an oncometabolite.	r-2-hydroxyglutarate	0-20	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	94-100	
32882760-1	2020	PURPOSE: Pharmacological inhibition of mutant isocitrate dehydrogenase (IDH) reduces R-2-hydroxyglutarate (2-HG) levels and restores cellular differentiation in vivo and in vitro.	r-2-hydroxyglutarate	85-105	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	46-70	
32882760-1	2020	PURPOSE: Pharmacological inhibition of mutant isocitrate dehydrogenase (IDH) reduces R-2-hydroxyglutarate (2-HG) levels and restores cellular differentiation in vivo and in vitro.	r-2-hydroxyglutarate	85-105	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	72-75	
30643428-2	2019	Neomorphic mutations in isoform 1 of isocitrate dehydrogenase (IDH1) result in the formation of the onco-metabolite R-2-hydroxyglutarate, which drives leukemic transformation by affecting processes such as chromatin remodeling, the cellular defense against oxidative stress and cell survival.	r-2-hydroxyglutarate	116-136	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	63-67	
27624942-3	2016	In gliomas and acute myeloid leukaemias, IDH1/2 mutations confer gain-of-function leading to production of the oncometabolite R-2-hydroxyglutarate (2HG) from alphaKG.	r-2-hydroxyglutarate	126-146	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	41-47	
28711227-3	2017	Gain-of-function mutations in IDH1/2 have been shown to stimulate production of the oncogenic metabolite R-2-hydroxyglutarate (R-2HG), which inhibits alpha-ketoglutarate (alphaKG)-dependent enzymes.	r-2-hydroxyglutarate	105-125	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	30-36	
28319047-2	2017	LGG-associated IDH mutations confer gain-of-function activity by converting alpha-ketoglutarate to the oncometabolite R-2-hydroxyglutarate (2HG).	r-2-hydroxyglutarate	118-138	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	15-18	
28132785-1	2017	Oncogenic IDH1 and IDH2 mutations contribute to cancer via production of R-2-hydroxyglutarate (2-HG).	r-2-hydroxyglutarate	73-93	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	10-14	
27245312-1	2016	BACKGROUND: Cancer-associated isocitrate dehydrogenase (IDH) mutations block normal cellular differentiation via production of the oncometabolite, R-2-hydroxyglutarate.	r-2-hydroxyglutarate	147-167	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	56-59	
27577048-1	2016	Mutations of isocitrate dehydrogenase 1 (IDH1) and IDH2 in acute myeloid leukemia (AML) cells produce the oncometabolite R-2-hydroxyglutarate (R-2HG) to induce epigenetic alteration and block hematopoietic differentiation.	r-2-hydroxyglutarate	121-141	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	13-39	
27577048-1	2016	Mutations of isocitrate dehydrogenase 1 (IDH1) and IDH2 in acute myeloid leukemia (AML) cells produce the oncometabolite R-2-hydroxyglutarate (R-2HG) to induce epigenetic alteration and block hematopoietic differentiation.	r-2-hydroxyglutarate	121-141	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	41-45	
26691210-1	2016	BACKGROUND: The majority of WHO grades II and III gliomas harbor a missense mutation in the metabolic gene isocitrate dehydrogenase (IDH) and accumulate the metabolite R-2-hydroxyglutarate (R-2HG).	r-2-hydroxyglutarate	168-188	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	107-131	
26691210-1	2016	BACKGROUND: The majority of WHO grades II and III gliomas harbor a missense mutation in the metabolic gene isocitrate dehydrogenase (IDH) and accumulate the metabolite R-2-hydroxyglutarate (R-2HG).	r-2-hydroxyglutarate	168-188	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	133-136	
23558169-4	2013	A selective R132H-IDH1 inhibitor (AGI-5198) identified through a high-throughput screen blocked, in a dose-dependent manner, the ability of the mutant enzyme (mIDH1) to produce R-2-hydroxyglutarate (R-2HG).	r-2-hydroxyglutarate	177-197	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	18-22	
26147657-1	2015	In recent years, frequent isocitrate dehydrogenase 1/2 (IDH1/IDH2) gene mutations were found in a variety of tumors, which specifically alter arginine residues of catalytic active site in IDH1/IDH2 and confer new enzymatic function of directly catalyzing alpha-ketoglutarate (alpha-KG) to R-2-hydroxyglutarate (2-HG).	r-2-hydroxyglutarate	289-309	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	56-60	
26147657-1	2015	In recent years, frequent isocitrate dehydrogenase 1/2 (IDH1/IDH2) gene mutations were found in a variety of tumors, which specifically alter arginine residues of catalytic active site in IDH1/IDH2 and confer new enzymatic function of directly catalyzing alpha-ketoglutarate (alpha-KG) to R-2-hydroxyglutarate (2-HG).	r-2-hydroxyglutarate	289-309	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	188-192	
26007236-3	2015	Mutant IDH1/IDH2 enzymes were reported to form an oncometabolite r-2-hydroxyglutarate (2HG), further strengthening malignancy.	r-2-hydroxyglutarate	65-85	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	7-11	
23518346-0	2013	R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis.	r-2-hydroxyglutarate	0-20	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	44-47	
23518346-1	2013	The tumor-associated isocitrate dehydrogenase (IDH) mutants are unique in that they have lost their normal catalytic activity and gained a novel function to produce R-2-hydroxyglutarate (R-2-HG).	r-2-hydroxyglutarate	165-185	isocitrate dehydrogenase (NADP(+)) 1	Homo sapiens	47-50